Morgan Stanley Just Published A Huge Biotech Stock Report Forecasting Double Revenue And Triple Cash Flow
Morgan Stanley
Some folks have speculated that biotechs have been in a bubble, and they also worry that the bubble may be bursting.
But Morgan Stanley's Matthew Harrison and Dr. David Friedman believe there's opportunity in this space.
The analysts initiate coverage on the sector with Amgen (price target: $140) and Bioden Idec ($395) at over-weight and Celgene ($150), Gilead ($75), Regeneron ($320) and Pharmacyclics ($120) at equal-weight.
"Our top pick is Biogen given upside to EU Tecfidera, Hemophilia and what we see as the best pipeline in the industry," they said. "We also favor Amgen as we see a business with durable cash flows and a lower risk pipeline that has been overlooked for its lack of one hit wonders. Among our four EWs, we see the most risk to Pharmacyclics based on duration of therapy and Gilead based on the sustainability of its HCV revs."
As you can see in the chart above, these stocks also have the potential to blow past those price targets. They also have the potential to collapse.
Investing In Biotechs
"Major de-risking events leading to new mega blockbusters have transformed the Big 4 Biotechs (Amgen, Biogen, Celgene and Gilead)," they wrote in a new 24-page note to clients. "We expect total group revenues to double from $175B over the last 5 years to $335B over the next 5 years and total cash flows to triple from $31B to $95B. Investors have rewarded the group with a return ~2.3x the S&P 500 over last 3 years."
Words like "double," "triple," and "mega-blockbuster" are what biotech stocks are all about. It's the epitome of speculation with high risk and high rewards.
Morgan Stanley
These analyst reports typically include charts like the one you see to the right.
It's a long-term path of estimated revenues.
As you can see, these companies offer the potential for - not the promise of - massive sales and profit growth.
Again, it's the potential for - not the promise of - massive growth.
- In second consecutive week of decline, forex kitty drops $2.28 bn to $640.33 bn
- SBI Life Q4 profit rises 4% to ₹811 crore
- IMD predicts severe heatwave conditions over East, South Peninsular India for next five days
- COVID lockdown-related school disruptions will continue to worsen students’ exam results into the 2030s: study
- India legend Yuvraj Singh named ICC Men's T20 World Cup 2024 ambassador